Testicular cancer starts in the testicles and usually affects one testicle. It most often occurs in young and middle‑aged men, typically between ages 15 and 45. Many people first hear about testicular cancer when they notice a painless lump, swelling, or a feeling of heaviness in the scrotum. It is highly treatable and often curable, and most people live long lives with timely care. Treatment usually includes surgery and may include chemotherapy, radiation, or surveillance, and follow‑up lasts for years to watch for recurrence.
Overview
Testicular cancerSymptoms
Early symptoms of testicular cancer often include a painless lump or swelling in one testicle, heaviness, or a dull ache in the groin or lower belly. Some notice breast tenderness, back pain, or shortness of breath if it spreads.
Outlook and prognosis
Most people with testicular cancer do very well, especially when it’s found early, and long-term survival is high. Even with spread, modern treatments often control the disease and preserve fertility for many. Follow-up is important to catch any return early.
Causes and risk factors
Testicular cancer risk rises with an undescended testicle, prior or family history, and specific genetic changes. It’s most common at ages 15–35 and more often in White men; HIV and infertility increase risk. Environmental and lifestyle links remain uncertain.
Genetic influences
Genetics play a modest role in testicular cancer. A family history, especially an affected father or brother, raises risk, and certain inherited variants slightly increase susceptibility. Most cases, however, occur without a known genetic cause.
Diagnosis
Doctors diagnose testicular cancer with a testicular exam and scrotal ultrasound. Blood tests check tumor markers. Definitive diagnosis of testicular cancer usually follows surgical removal of the affected testicle, with CT scans to stage spread.
Treatment and drugs
Testicular cancer is highly treatable with tailored care. Most people do well with surgery to remove the affected testicle, followed by active surveillance, chemotherapy, radiation, or targeted treatments based on tumor type and stage. Care teams also manage fertility preservation and long‑term follow‑up.
Symptoms
Testicular cancer often shows up as changes in one testicle that are easy to miss at first. Common early symptoms of testicular cancer include a painless lump, swelling, or a sense of heaviness in the scrotum. Symptoms vary from person to person and can change over time. You might notice a firm area while showering or dressing, or a dull ache after sitting for a long time.
A firm, painless lump or nodule in one testicle is a common early sign of testicular cancer. It may feel like a small, hard bead under the skin.
One testicle may look or feel larger than usual. Underwear may feel tighter on one side, or the scrotum may look fuller.
A dragging or heavy sensation in the scrotum is common for some. It may be more noticeable after standing or at the end of the day.
The testicle may feel harder, or its shape may seem different from the other side. Some notice an uneven or bumpy surface.
How people usually first notice Testicular cancer?
Many people first notice testicular cancer as a painless lump or swelling in one testicle, or a feeling that one testicle is heavier or different from the other. Some also spot a dull ache in the lower belly or groin, a sudden buildup of fluid in the scrotum, or breast tenderness from hormone changes, while doctors may find firmness or an irregular surface on exam. If you notice any new lump or lasting change in a testicle, it’s important to see a clinician promptly—most cases are found early and are highly treatable.
Types of Testicular cancer
Testicular cancer has a few well-recognized types, and symptoms can vary depending on which one is present and how advanced it is. People may notice a painless lump, a feeling of heaviness, or a dull ache in the scrotum or lower belly, while other signs depend on the specific cell type. When people talk about types of testicular cancer, they usually mean the main tumor groups seen under the microscope, which helps guide treatment and expected outcomes. Not everyone will experience every type.
Seminoma
Often shows up as a painless, slow-growing testicular lump. It tends to be found a bit earlier and usually spreads more gradually. Early symptoms of testicular cancer in this group may be subtle.
Non-seminoma
Usually grows faster and may cause symptoms to appear sooner. People may notice a firmer lump, more rapid testicular changes, or symptoms from spread such as back pain. Blood tests often show higher tumor markers.
Mixed germ cell
Contains both seminoma and non-seminoma components. Symptoms can overlap, with a painless lump in some and quicker changes in others. Treatment is guided by the most aggressive component.
Stromal tumors
Arise from the testicle’s supporting cells, such as Leydig or Sertoli cells. These are less common and may cause hormone-related changes like breast tenderness or early puberty in children. Lumps are often small and found during an exam or ultrasound.
Carcinoma in situ
Abnormal cells are present inside the testicle but haven’t formed an invasive tumor. There may be no symptoms, and it’s often found during evaluation for infertility or an undescended testicle. Care plans aim to prevent progression to invasive cancer.
What genetics can tell you about symptoms
Some testicular cancers run in families due to inherited variations in genes that control cell growth, making tumors more likely and sometimes appearing at a younger age. Certain changes in DNA repair genes can also raise risk, leading to faster-growing or bilateral tumors.
Causes and risk factors
The exact cause of testicular cancer is not known, and risk factors for testicular cancer vary by person. Risk rises with an undescended testicle (cryptorchidism), a prior testicular cancer, and a close family history, but many with these risks never develop cancer. It is also higher in teens and young adults, in people of Northern European ancestry, and in those living with HIV. Evidence for specific environmental exposures is limited. Doctors distinguish between risk factors you can change and those you can’t, and early repair of an undescended testicle and safer sex to reduce HIV may lower risk.
Environmental and biological risk factors
Testicular cancer risk comes from a mix of factors in the body and the world around you. Doctors often group risks into internal (biological) and external (environmental). Risk factors raise the chance of cancer but do not guarantee it will occur. Risk factors are different from early symptoms of testicular cancer, which involve changes you can feel or see.
When a testicle does not move down into the scrotum before birth, the chance of testicular cancer is higher. Surgery to bring it down lowers other complications but risk stays above average.
A history of testicular cancer in one testicle raises the chance in the other. This higher risk can last for many years. Regular follow-up can support early detection.
Abnormal cells found on a testicular biopsy can later turn into cancer. Monitoring or treatment may be recommended to lower that risk.
Risk is highest from the late teens through the mid-30s. It can still occur at other ages, just less often.
Genetic risk factors
Inherited factors play a meaningful role in who develops testicular cancer, but for most people there isn’t a single high‑risk gene. Risk is not destiny—it varies widely between individuals. Family patterns and certain chromosome changes can raise odds, and some genetic backgrounds show higher rates. Genetics don’t change the early symptoms of testicular cancer, but they can influence who is more likely to develop it.
Family history: Having a father or brother with testicular cancer greatly increases risk. Risk may be about fourfold with an affected father and around eightfold with an affected brother. This pattern points to inherited susceptibility.
Multiple gene effects: Most inherited risk comes from many small DNA changes working together, rather than one powerful gene. Each change nudges risk only a little, but together they can have a noticeable impact.
Y chromosome deletions: Small missing pieces in a sperm‑production region of the Y chromosome are linked to a slightly higher chance of testicular cancer. These changes can be inherited or can arise for the first time.
Northern European ancestry: People with this genetic background have higher rates of this cancer. The difference likely reflects inherited risk variants that are more common in these populations.
Sex development differences: Certain variations in sex chromosomes or testicular development raise germ cell tumor risk. Doctors may recommend closer follow‑up in these situations.
Prior testis cancer: Having had cancer in one testicle increases the chance of developing it in the other later on. This likely reflects shared genetic susceptibility across both testes.
Rare genetic syndromes: Uncommon inherited conditions that affect body development or tumor‑suppressor pathways can raise germ cell tumor risk. These syndromes account for only a small fraction of testicular cancer cases.
No single high-risk gene: Most families do not share one mutation that explains all cases. That is why routine clinical genetic testing for risk alone is not usually helpful.
Lifestyle risk factors
Lifestyle risk factors for testicular cancer are less well established than for many other cancers, but several behaviors have been studied. Evidence varies in strength; where data are mixed, cautious phrasing is used. Below are elements that reflect current research on how lifestyle affects testicular cancer, aiming to clarify potential lifestyle risk factors for testicular cancer.
Frequent marijuana use, especially beginning in adolescence, has been linked in several studies to higher risk of testicular germ cell tumors. Evidence is mixed and not definitive, but reducing heavy or early use may lower potential risk.
Regular physical activity is associated in some studies with a modestly lower risk of testicular cancer. Consistent exercise may help by influencing hormone balance and body composition.
Having HIV, particularly with immune suppression, is linked to increased risk of seminoma. Safer sex practices, PrEP, and treatment that maintains viral suppression may indirectly reduce this cancer risk.
Nonmedical use of anabolic-androgenic steroids can disrupt testicular hormones and shrink testicular tissue. Limited research raises concern about a possible link to testicular tumors, so avoidance is prudent.
Risk prevention
You can’t fully prevent testicular cancer, but you can lower risk of late detection and catch problems early. Prevention works best when combined with regular check-ups. Focus on knowing what’s normal for you, acting quickly on changes, and getting tailored advice if you have higher risk. If you’re a parent or caregiver, timely care for an undescended testicle can reduce future risk.
Get familiar with how your testicles normally look and feel. If you notice a painless lump, heaviness, swelling, or a change in shape or firmness, book a visit promptly.
A brief monthly self-check can help some people spot changes sooner. It hasn’t been proven to lower deaths from testicular cancer, but it can lead to earlier evaluation. Ask a clinician to show you a simple, correct technique.
If you had an undescended testicle, prior testicular cancer, or a close family history, schedule regular genital exams. Your clinician may suggest a personalized plan and a low threshold for ultrasound if something feels off.
For children with an undescended testicle, surgical correction lowers long-term risk of testicular cancer. Discuss timing with a pediatric urologist, ideally between 6 and 18 months of age. Even after repair, lifelong awareness still matters.
Transmission
Testicular cancer cannot be transferred between people; it isn’t contagious. It does not spread through sex, kissing, skin-to-skin contact, toilets, or shared items, and being around someone with testicular cancer poses no risk to you. People sometimes ask about how testicular cancer is inherited; the cancer itself is not passed down, though having a father or brother with it can raise your own risk slightly because some inherited traits can make it more likely. Most testicular cancer starts from random changes in testicular cells, not from genetic transmission of testicular cancer, so there’s no infectious period and no need for isolation.
When to test your genes
Consider genetic testing if you were diagnosed with testicular cancer at a young age, have bilateral tumors, or have close relatives (especially brothers) with testicular cancer or multiple germ cell tumors. People with a strong family history or from high‑incidence families may benefit from counseling and targeted testing. Testing can guide surveillance, fertility planning, and tailored follow-up.
Diagnosis
You might notice a painless lump, a feeling of heaviness, or swelling in one testicle that makes everyday activities or workouts feel different. These changes usually prompt a check-up, where the path to answers moves quickly. Getting a diagnosis is often a turning point toward answers and support. Here’s how testicular cancer is diagnosed in most clinics today.
Doctors usually begin with a focused exam of the scrotum, groin, and abdomen and ask about symptoms and risk factors such as an undescended testicle. This helps decide which tests come next.
A quick, painless scan uses sound waves to show whether a lump is solid or fluid-filled and where it sits inside the testicle. Solid masses raise concern and guide the next steps in the diagnosis of testicular cancer.
Blood tests check alpha-fetoprotein (AFP), beta-hCG, and LDH, which can be elevated with certain testicular tumors. Not every cancer raises these markers, but when high, they support the diagnosis and help with staging and follow-up.
The affected testicle is removed through a small groin incision so a pathologist can confirm the exact tumor type under the microscope. Needle biopsy through the scrotum is avoided because it can spread cells; surgery provides a definitive diagnosis and is also the first treatment.
Stages of Testicular cancer
Staging shows how far testicular cancer has grown or spread and helps tailor treatment. Different tests may be suggested to help map the cancer, including an exam, ultrasound, blood tumor markers, and scans of the abdomen and chest. Early symptoms of testicular cancer—like a painless lump or a feeling of heaviness in the scrotum—often appear before staging is done, but staging determines the next steps after diagnosis.
Stage I localized
Cancer is only in the testicle and has not spread to lymph nodes or other organs. Blood tumor markers may be normal or raised, but scans show no spread.
Stage II nodes
The cancer has spread to nearby lymph nodes deep in the abdomen. The size and number of affected nodes help sort this into smaller groups.
Stage III distant
The cancer has reached distant organs such as the lungs or liver, or tumor marker levels are very high. This stage can also include spread to lymph nodes.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially right after a diagnosis of testicular cancer. The outlook is generally very good, even when the cancer has spread, because testicular cancer responds well to surgery and modern chemotherapy. Five-year survival in high-income countries is above 95% overall, and for early-stage disease it’s close to 99%. For metastatic disease, survival ranges widely by risk group, but many people are cured; deaths do still occur, most often within the first few years if the cancer does not respond to treatment.
Looking at the long-term picture can be helpful. Most people who finish treatment return to work, school, and exercise, though energy and mood may take weeks to months to rebound. Doctors call this the prognosis—a medical word for likely outcomes. Early symptoms of testicular cancer that prompt quick evaluation, like a painless testicular lump, often lead to earlier-stage diagnosis and the best chance of cure.
Over time, most people live cancer-free, but follow-up is important to catch rare recurrences and manage late effects. Chemotherapy and radiation can raise risks for infertility, heart disease, or second cancers later on, so care teams tailor surveillance with physical exams, tumor markers, and imaging on a set schedule. With ongoing care, many people maintain excellent long-term health and life expectancy similar to peers without cancer. Talk with your doctor about what your personal outlook might look like, including fertility options before treatment, your individual risk group, and a follow-up plan that fits your life.
Long-term effects
Life after testicular cancer often involves routine checkups and getting used to how your body feels now. Some long-term effects come from the cancer itself, while many are tied to surgery, chemotherapy, or radiation. Long-term effects vary widely, and most people return to active lives with the right follow-up. Your care team will watch for late effects and help you manage any changes that show up months or years later.
Sperm counts can drop after chemotherapy or radiation, sometimes leading to subfertility. Removal of one testicle usually preserves fertility, but some may still struggle to conceive. Sperm banking before treatment is often recommended.
Losing a testicle or testicular damage can lower testosterone. This can lead to low energy, reduced sex drive, mood changes, and loss of muscle mass. Replacement therapy may be considered if levels stay low.
Some notice difficulty with erections or orgasm after treatment. Nerve-sparing surgery helps, but certain procedures can affect ejaculation or cause dry orgasms. Open conversation with your care team can guide solutions.
Scars, a missing testicle, or weight changes can affect confidence. Anxiety, depression, or fear of recurrence can linger even after cure. Testicular prostheses and counseling can help with adjustment.
How is it to live with Testicular cancer?
Living with testicular cancer often means moving through a fast, focused stretch of treatment while juggling work, relationships, and the shock of a cancer diagnosis at a young age. Day to day, people may deal with surgery recovery, temporary fatigue or nausea from chemotherapy, body-image changes after losing a testicle, and worries about fertility—though sperm banking before treatment and modern prosthetics can help many feel more prepared and comfortable. Partners, family, and friends are affected too; they may feel fear and protective concern, but clear information, open conversation about sexual health and fertility, and practical support with appointments or household tasks can ease the load. Many find that follow-up visits bring mixed feelings—reassurance from close monitoring alongside “scanxiety”—and that connecting with peer support normalizes the experience and restores confidence.
Treatment and drugs
Testicular cancer is very treatable, and care is tailored to the type of tumor and how far it has spread. Most people start with surgery to remove the affected testicle, and many recover fully with surgery alone; if needed, doctors may add chemotherapy, targeted radiation, or both to lower the chance of the cancer coming back. Not every treatment works the same way for every person, so your team will match options to your tumor type (seminoma or non-seminoma), stage, and your plans for fertility, with sperm banking discussed before treatment when possible. Some treatments fit easily into your routine, while others—like multi-week chemotherapy—require more clinic time and careful follow-up for side effects, which are often manageable and temporary. After treatment, regular check-ins with scans and blood tests help catch any return early and guide any maintenance steps if they’re needed.
Non-drug treatment
Care for testicular cancer isn’t only surgery or chemotherapy. Alongside medicines, non-drug therapies can ease side effects, protect fertility, and support recovery. These approaches can help with energy, mood, sexual health, and day-to-day life. Your team can tailor them to your stage, treatment plan, and goals.
Close monitoring with exams, blood tests, and scans can safely track the cancer after treatment or when risk is very low. It helps avoid unnecessary procedures while keeping a close eye on changes.
Freezing sperm before treatment protects future family-building options. It’s done quickly at a fertility clinic, often within days.
Counseling can address erection changes, ejaculation concerns, and libido shifts after treatment. Practical strategies and partner communication often restore confidence and comfort.
Supervised activity can reduce fatigue, rebuild strength, and improve mood. A physiotherapist can tailor a plan that fits your energy level and treatment schedule.
Your genes may have an impact on how drugs work for you
Medicines for testicular cancer can work differently based on your genes, which influence how you process chemotherapy and how sensitive tumor cells are to certain drugs. Genetic testing sometimes helps tailor doses, reduce side effects, and choose the most effective regimen.
Pharmacological treatments
Most people with testicular cancer are treated—and often cured—with chemotherapy. First-line chemotherapy for testicular cancer usually combines several drugs to kill cancer cells throughout the body. First-line medications are those doctors usually try first, based on how well they work and their safety. Supportive medicines are used alongside treatment to prevent nausea, protect blood counts, and manage side effects so you can stay on track.
Standard first-line regimens include BEP (bleomycin, etoposide, cisplatin) or EP (etoposide, cisplatin) when bleomycin isn’t suitable. These are given in cycles over several weeks and aim for cure, especially in early or good‑risk metastatic disease. Common effects include nausea, hair loss, fatigue, and numbness in fingers or toes.
One or two cycles of carboplatin may be offered after surgery for stage I seminoma to lower the risk of return. It’s an alternative to radiation or active surveillance. Side effects are usually milder than multi‑drug regimens but can still include low blood counts and fatigue.
VIP (etoposide, ifosfamide, cisplatin) is used when bleomycin isn’t advised or for bulky disease. It’s more intensive and often needs growth‑factor support to reduce infection risk. Kidney and bladder irritation, low blood counts, and fatigue are monitored closely.
TIP (paclitaxel, ifosfamide, cisplatin) is a common option if cancer returns after initial therapy. It’s intensive and may require hospital stays during cycles. Nerve tingling, low blood counts, and nausea are watched and managed.
Genetic influences
Some families have more than one person diagnosed with testicular cancer, and that pattern points to genetics playing a role. Family history is one of the strongest clues to a genetic influence. If a father or brother has had testicular cancer, your own chance is higher—often about two to eight times higher than someone without that history—but many with a family link never develop it. For most people, there isn’t a single “testicular cancer gene”; instead, many common gene differences each nudge risk a little, interacting with other factors across a lifetime. Undescended testicle and certain differences in testicular development can also raise risk, and these traits sometimes run in families for both genetic and non-genetic reasons. Because of this mix, routine genetic testing isn’t recommended for everyone; if several relatives have been affected or someone was diagnosed at a very young age, a genetic counselor can review your family history and whether genetic testing for testicular cancer risk could be helpful.
Is Testicular cancer genetic?
Genetics play a modest role in testicular cancer. A family history, especially an affected father or brother, raises risk, and certain inherited variants slightly increase susceptibility. Most cases, however, occur without a known genetic cause.
Pharmacogenetics—how genetics influence drug effects
Treatment for testicular cancer often involves cisplatin-based chemotherapy, and inherited differences in your genes can influence how your body handles these drugs and the side effects you experience. Two people on the same medicines may face different risks of hearing changes or kidney strain with cisplatin, or lung irritation with bleomycin, partly due to small differences in how their bodies move and clear these drugs. Studies are exploring these links, but pharmacogenetic testing for testicular cancer isn’t routinely used to choose doses or drugs yet. Genetics is only one factor; age, kidney function, other medicines, and total dose play a big role in how you respond. Tumor DNA testing is sometimes used in research or after relapse, but most first treatments still rely on stage, tumor markers, and imaging because standard regimens work well for many. If you’ve had unexpected side effects in the past, talk with your oncology team about whether any genetic factors could be relevant to your plan.
Interactions with other conditions
For many, other health issues can shape how testicular cancer is found and treated. Infections or inflammation in the scrotum, such as epididymitis, can look and feel similar to early symptoms of testicular cancer, which sometimes leads to delays in diagnosis. Lung, kidney, or heart conditions may influence chemotherapy choices and side effects—bleomycin can worsen existing lung problems, and cisplatin can strain the kidneys and raise the chance of long‑term high blood pressure and heart disease. If you already live with cardiovascular risk factors, diabetes, or obesity, your care team may watch more closely for metabolic changes after treatment and plan heart‑healthy follow‑up. People living with HIV are usually treated with standard regimens for testicular cancer, but infection risks and drug interactions need careful coordination across specialists. Ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described swollen, painful testicles and unexplained lumps, often in hushed tones because of stigma. A young man in his 20s might have noticed one testicle felt heavier in the bath, or a partner might have spotted a firm area that didn’t go away. Before modern surgery and imaging, many with testicular cancer faced late diagnoses and limited options, and loss of fertility and high mortality were common.
First described in the medical literature as hard, enlarging masses of the testicle, testicular cancer was initially grouped with other “tumors of the genitals,” with little understanding of types. In the late 1800s, surgeons refined techniques to remove the affected testicle, which improved survival for some. As the 20th century progressed, pathologists learned that most cases were “germ cell tumors,” and they began to separate seminoma from nonseminoma under the microscope. This shift mattered: it helped doctors choose treatments and estimate outcomes more accurately.
In recent decades, knowledge has built on a long tradition of observation. Imaging such as ultrasound made it easier to spot early symptoms of testicular cancer, confirm a lump was solid rather than a fluid-filled cyst, and plan surgery. Blood tests for tumor markers—including alpha‑fetoprotein and beta‑hCG—gave doctors a way to track disease activity over time. These tools meant more people were diagnosed at earlier stages, when cure is most likely.
The biggest turning point arrived in the 1970s and 1980s with combination chemotherapy, especially regimens based on cisplatin. Survival rates climbed rapidly, even for those with cancer that had spread to lymph nodes or lungs. Radiation therapy techniques also became more precise for seminoma, reducing exposure to healthy tissues. With each decade, care shifted toward balancing cure with long-term health, including protecting fertility and sexual function whenever possible.
Public awareness followed. Campaigns encouraged testicular self-exam and normalised talking about testicular changes, so more people sought care sooner. Registries in Europe and the United States showed that while testicular cancer remained uncommon overall, it became the most common solid cancer in young adult men. They also documented rising survival, which today exceeds 95% in many high‑income countries.
Advances in genetics helped explain patterns that families and clinicians had noticed: a higher risk in those with a history of undescended testicle, certain inherited factors that nudge risk upward, and differences among populations. Modern research continues to explore why rates vary by ancestry and geography, aiming to refine prevention and follow-up.
Looking back helps explain why today’s guidance emphasizes quick evaluation of any persistent testicular lump, ultrasound to characterize it, prompt surgery when needed, and thoughtful use of chemotherapy or radiation. The history of testicular cancer is ultimately one of steady progress—from fear and silence to highly effective, carefully tailored care.